Bone morphogenetic proteins (BMPs) are a unique group of growth factors or cytokines that act as metabologens. They are part of a familay called transforming growth factors.
To date over 20 members have been identified during processes such as embryogenesis, skeletal formation, hematopoesis and neurogenesis. Though their functions have been identified, much less is known about their regulation and activation.
BMPs were first discovered when scientists were testing for molecules that had the ability to induce the formation of bone and cartilage. Their existence however we hypothesized much earlier and goes back to Hippocrates, the father of Western Medicine. He was the first to articulate that bone had regeneration and repair potential.
The first therapies utilizing these molecules began with the use of decalcified bone, which was implanted into the body to treat osteomyelitis and other bone diseases. At the time, it was suggested that a hypothetical substance, called osteogenin, was responsible for initiating bone growth.
The basis of bone morphogenesis is due then to the demineralized segments of bone, which induced new bone formation. This discovery was published in 1965 and the name "Bone Morphogenetic Protein" was given to these demineralized proteins.
Bone induction involves a cascade of cell reactions involving chemotaxis, mitosis, and differentiation.
BMPs are considered a unique group of demineralized proteins that initiate morphogenetic signals to promote proper bone tissue architecture.
BMPs have been used in dentistry to rebuild lost bone and in spinal surgery where it is surgically implanted.
The use of BMPs as an oral adjunct to alleviate arthritis and other bone disorders in relatively new.
The functioning of BMP signals depends on regulating healthy signals and blocking pathological ones.
Cancer for example, often involves the ms-regulation of the BMP signalling system.
Absence of BMP signalling is, for instance, an important factor in the progression of colon cancer, and conversely, the overactivation of BMP signalling causes reflux-induced esophagitis and Barrett's esophagus. This is instrumental in the development of adenocarcinoma in the proximal portion of the gastrointestinal tract.
Recombinant human BMPs are used in orthopedic applications such as spinal fusions and oral surgery.
rhBMP-2 and rhBMP-7 are Food and Drug Administration (FDA)-approved for some uses. rhBMP-2 causes more overgrown bone than any other BMPs and is widely used off-label.
Ostinol™ is a proprietary protein that is believed to stimulate bone and cartilage formation.
It contains the stimulating protein, Cyplexinol.
According to the manufacturer
"Ostinol™ Bone and Cartilage Stimulating Proteins: The only product to contain the powerful Bone Morphogenetic Proteins (BMPs)
- Natural Anti-inflammatory properties
The BMPs within Ostinol™ inhibit the Interlukin-1 (IL-1) pro-inflammatory cytokines, thus reducing inflammation
- Grows Bone and Cartilage Tissue
The BMPs within Ostinol™ stimulate and activate stem cells to become osteoblasts and chondrocytes which grow bone and cartilage tissue"
Cyplexinol® is a partially hydrolyzed collage/BMP- complex, which contains:
- BMPs (Bone Morphogenetic Proteins)
- TGF-Beta (Transforming Growth Factor Beta)
- IGF (Insulin-like Growth Factor)
- bFGF (Basic Fibroblastic Growth Factor)
- VEGF (Vascular Endothelial Growth Factor)
Cyplexinol® (Nature’s BMP – complex):
- Naturally activates bone & cartilage growth*
- Is functionally involved in bone & cartilage formation*
- Help maintain natural bone & joint homeostasis*
- Has a natural immunoprotective effects against inflammation*